Published in Cancer Weekly, May 29th, 2007
During the three months period ended 31 March 2007, operating expenses amounted to DKK 55.0 million against DKK 45.5 million in the year-earlier period, primarily due to the establishment of Savene(tm) sales forces in Europe and the USA. The operating loss for the period was DKK 44.5 million, compared with DKK 38.5 million in the same period of last year. The company posted a loss before tax of DKK 42.6 million in the first three months of 2007 against a pre-tax loss of DKK 37.1 million in the same period of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.